SOST and osteoporosis: Sclerostin acts by binding to the Wnt coreceptor LRP5/6 by competing with Wnt protein; as a consequence, sclerostin blocks the accumulation of β-catenin in the cytoplasm, inhibits the differentiation and proliferation of osteoblasts, enhances osteoclastogenesis and causes bone loss.108,109 Given the inhibitory effect of sclerostin on osteoblast function and bone formation, blocking the activity of sclerostin to activate this pathway seems to be a potential strategy in the treatment of osteoporosis.